Introduction: Metabolic Syndrome (MetS) and depression comorbidity has been recognized, but its directionality is still uncertain. The aims of this study was to assess the association between depression (diagnosis and severity) and MetS (components, diagnosis and trajectory) in the baseline and over a 4-year follow-up period.
Material And Methods: Baseline and follow-up data from 13,883 participants of the Brazilian Longitudinal Study of Adult Health were analyzed. The Clinical Interview Schedule Revised assessed depressive episode and its severity. MetS components and diagnosis were assessed according to the National Cholesterol Education Program Adult Treatment Panel III. Participants were grouped according to MetS trajectory as recovered, incident and persistent MetS. Logistic regression analysis was conducted estimating odds ratios (OR) and 95% confidence intervals (95%CI).
Results: Baseline depression was positively associated with recovered (OR = 1.59, 95%CI 1.18-2.14), incident (OR = 1.45, 95%CI 1.09-1.91) and persistent (OR = 1.70, 95%CI 1.39-2.07) MetS. Baseline depression was also associated with large waist circumference (OR = 1.47, 95%CI 1.23-1.75), high triglycerides (OR = 1.23, 95%CI 1.02-1.49), low high-density lipoprotein cholesterol (OR = 1.30, 95%CI 1.08-1.56), and hyperglycemia (OR = 1.38, 95%CI 1.15-1.66) at follow-up. Having three or more MetS components at follow-up was associated with baseline depression, with a positive dose-response effect (OR = 1.77, 95%CI 1.29-2.43; OR = 1.79, 95%CI 1.26-2.54; OR = 2.27, 95%CI 1.50-3.46, respectively). The magnitude of associations was greater in severe depression, when compared to moderate and mild.
Discussion: These results support that depression is a risk factor for the development of MetS and highlights the need to follow metabolic and cardiovascular alterations in the presence of depression.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jpsychires.2022.12.017 | DOI Listing |
Cureus
November 2024
Community Medicine, Sri Devaraj Urs Medical College, Sri Devaraj Academy of Higher Education and Research, Kolar, Karnataka, IND.
Background A major challenge in the treatment of MetS is the prevalence of low rates of adherence to the treatment regimen for individual components by the affected persons. This study aimed to estimate the medication adherence level among those with metabolic syndrome, determine the factors significantly associated with low adherence to medication, and explore the reasons for poor adherence to medication Materials and methods This sequential explanatory type of mixed method study was conducted among the metabolic syndrome patients attending the lifestyle clinic of a tertiary care hospital in the Salem district of Tamil Nadu, India. For the quantitative component, 210 was the sample size and for the qualitative component, the sample size was six.
View Article and Find Full Text PDFSci Rep
December 2024
Total Healthcare Center, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Early detection of a premetabolic status that is at risk for metabolic syndrome (MetS) but not meeting the criteria is crucial. This study examined 27,623 participants aged 20-50 (mean: 40.7) years who underwent initial health screening at Kangbuk Samsung Hospital (2011-2019), focusing on individuals with one or two MetS components.
View Article and Find Full Text PDFMetabolites
December 2024
Internal Medicine II Department, Faculty of Medicine, University of Medicine, and Pharmacy "Grigore T. Popa", 700115 Iasi, Romania.
: LL-37 is associated with metabolic syndrome (MetS), a constellation of risk factors comprising obesity, insulin resistance (IR), dyslipidemia, and hypertension, which elevates the risk of cardiovascular disease and type 2 diabetes. : In this narrative review, we analyzed the literature focusing on recent developments in the relationship between cathelicidin and various components of MetS to provide a comprehensive overview. : Studies have shown that LL-37 is linked to inflammation in adipose tissue (AT) and the development of IR in obesity.
View Article and Find Full Text PDFMetabolites
November 2024
Division of Cardiology, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul 05030, Republic of Korea.
Metabolic syndrome (MetS), a cluster of metabolic dysregulations, is recognized as a significant risk factor for the development of heart failure (HF). The pathophysiological mechanisms linking MetS to HF are complex and multifaceted, with the components of MetS contributing to cardiac deterioration through impaired myocardial energy metabolism, increased inflammation, and endothelial dysfunction. Numerous clinical studies have confirmed the relationship between MetS and HF.
View Article and Find Full Text PDFEndocrine
December 2024
Diabetes & Metabolism Clinic, 2nd Department of Pediatrics, "P. & A. Kyriakou" Children's Hospital, Athens, Greece.
Aim: Irisin, a newly discovered adipomyokine, has pleiotropic effects in metabolic and energy homeostasis, insulin resistance (IR), and browning of white adipose tissue. The aim of this study was to evaluate irisin levels in children with obesity and also to elucidate possible relationships between irisin with anthropometric obesity indices, parameters of metabolic syndrome (MetS), and intima media thickness (IMT).
Methods: A total of 77 prepubertal children, 4-12 years old, were enrolled in this study, including 44 children with obesity (BMI ≥ 95th percentile) and 33 normal weight controls of matched age and gender.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!